Black Canyon Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Black Canyon Bio is a private, pre-clinical stage biotech founded in 2021, headquartered in Denver, USA, and focused on the cancer vaccine sector. Its core asset is the SNAP platform, which aims to overcome key challenges in targeting patient-specific neoantigens to improve immunotherapy outcomes. The company's lead program, SNAPduo 101, a peptide vaccine for virus-associated cancers, is slated to enter clinical trials in 2026, positioning it in the competitive but high-potential field of personalized cancer vaccines.

Oncology

Technology Platform

Proprietary Specific Neo-Antigen Peptides (SNAP) platform designed to credential patient-specific tumor neoantigens to enhance the efficacy of cancer immunotherapies, with a focus on overcoming challenges in solid tumors.

Opportunities

The recent validation of personalized mRNA cancer vaccines has created a significant market opportunity and investor interest in neoantigen-based therapies.

Focusing initially on virus-associated cancers provides a clearer developmental pathway with defined antigens, potentially de-risking the first clinical entry.

Risk Factors

The company faces high scientific risk as its unproven SNAP platform must demonstrate superior neoantigen selection in humans.

As a pre-revenue, private company, it is vulnerable to financing risks and potential delays in its ambitious 2026 clinical timeline.

Competitive Landscape

The field of personalized cancer vaccines is highly competitive, with numerous well-funded biotechs (e.g., BioNTech, Moderna, Gritstone) and large pharma companies advancing platforms. Black Canyon Bio must differentiate its SNAP credentialing approach to capture value in this crowded space.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →